A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia

References

1. ↵
   1. World Health Organization

   (2002) The importance of pharmacovigilance. Safety monitoring of medicinal product (WHO, Geneva (CH)).
2. ↵
   1. US Food And Drug Administration

   (1999) Managing the risks from medical product use. Creating a risk management framework (US Food And Drug Administration, Rockville (MD)).
3. ↵
   1. Dal Pan GJ

   (2014) Ongoing challenges in pharmacovigilance. Drug Saf 37:1–8.

   OpenUrl
4. ↵
   1. Olsson S

   UR45 UPPSALA reports, Kick-off for pharmacovigilance in Saudi Arabia. Available from URL:http://who-umc.org/graphics/24355.pdf. Cited 2009 April; Accessed 2015 July 18.
5. ↵
   1. Alshammari TM,
   2. Al-Kathiri WH,
   3. Le Louet H,
   4. Aljadhey HS

   (2015) Completeness of adverse drug reactions reports of the Saudi adverse event reporting system. Saudi Med J 36:821–828.

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Mahmoud MA,
   2. Alswaida Y,
   3. Alshammari T,
   4. Khan TM,
   5. Alrasheedy A,
   6. Hassali MA,
   7. et al.

   (2014) Community pharmacists’ knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm J 22:411–418.

   OpenUrl
7. 1. Bawazir S

   (2006) Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction reporting. Saudi Pharm J 14:75–83.

   OpenUrl
8. ↵
   1. Khan TM

   (2013) Community pharmacists’ knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia. Ther Adv Drug Saf 4:45–51.

   OpenUrlCrossRefPubMed
9. ↵
   1. Moore N

   (2010) Improving pharmacovigilance in Europe. BMJ 340:c1694.

   OpenUrlFREE Full Text
10. ↵
    1. Anderson C

    (2010) Presenting and evaluating qualitative research. Am J Pharm Educ 74:141.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. Lopez-Gonzalez E,
    2. Herdeiro MT,
    3. Piñeiro-Lamas M,
    4. Figueiras A,
    5. GREPHEPI group

    (2015) Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Saf 38:189–196.

    OpenUrl
12. ↵
    1. Ribeiro-Vaz I,
    2. Santos C,
    3. da Costa-Pereira A,
    4. Cruz-Correia R

    (2012) Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Saf 35:387–394.

    OpenUrlPubMed
13. ↵
    1. Ruud KW,
    2. Srinivas SC,
    3. Toverud EL

    (2010) Addressing gaps in pharmacovigilance practices in the antiretroviral therapy program in the Eastern Cape Province, South Africa. Res Social Adm Pharm 6:345–553.

    OpenUrlPubMed
14. ↵
    1. Khan SA,
    2. Goyal C,
    3. Chandel N,
    4. Rafi M

    (2013) Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study. J Nat Sci Biol Med 4:191–196.

    OpenUrl
15. 1. Hardeep Bajaj JK,
    2. Rakesh K

    (2013) A survey on the knowledge, attitude and the practice of pharmacovigilance among the health care professionals in a teaching hospital in northern India. J Clin Diagn Res 7:97–99.

    OpenUrl
16. 1. Adedeji WA,
    2. Ibraheem WA,
    3. Fehintola FA

    (2013) Attitude and practice of doctors toward adverse drug reactions (ADRs) reporting in a Nigerian tertiary health facility. Ann Ib Postgrad Med 11:77–80.

    OpenUrl
17. 1. Desai CK,
    2. Iyer G,
    3. Panchal J,
    4. Shah S,
    5. Dikshit RK

    (2011) An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res 2:129–36.

    OpenUrlPubMed
18. 1. Vessal G,
    2. Mardani Z,
    3. Mollai M

    (2009) Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran. Pharm World Sci 31:183–187.

    OpenUrlPubMedWeb of Science
19. 1. Aziz Z,
    2. Siang TC,
    3. Badarudin NS

    (2007) Reporting of adverse drug reactions: predictors of under-reporting in Malaysia. Pharmacoepidemiol Drug Saf 16:223–228.

    OpenUrlCrossRefPubMed
20. 1. Irujo M,
    2. Beitia G,
    3. Bes-Rastrollo M,
    4. Figueiras A,
    5. Hernández-Díaz S,
    6. Lasheras B

    (2007) Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf 30:1073–1082.

    OpenUrlPubMed
21. 1. Bello SO,
    2. Umar MT

    (2011) Knowledge and attitudes of physicians relating to reporting of adverse drug reactions in Sokoto, north-western Nigeria. Ann Afr Med 10:13–18.

    OpenUrlPubMed
22. ↵
    1. Elnour AA,
    2. Ahmed AD,
    3. Yousif MA,
    4. Shehab A

    (2009) Awareness and reporting of adverse drug reactions among health care professionals in Sudan. Jt Comm J Qual Patient Saf 35:324–329.

    OpenUrlPubMed
23. ↵
    1. Vallano A,
    2. Cereza G,
    3. Pedròs C,
    4. Agustí A,
    5. Danés I,
    6. Aguilera C,
    7. et al.

    (2005) Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol 60:653–658.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    1. de Langen J,
    2. van Hunsel F,
    3. Passier A,
    4. de Jong-van den Berg L,
    5. van Grootheest K

    (2008) Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 31:515–524.

    OpenUrlCrossRefPubMedWeb of Science